Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reiterated by Cowen and Company in a research report issued on Thursday. They currently have a $232.00 price objective on the biopharmaceutical company’s stock. Cowen and Company’s target price suggests a potential upside of 164.96% from the stock’s previous close.

Several other research analysts have also issued reports on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $221.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday. Robert W. Baird reiterated an “outperform” rating and issued a $332.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday. Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday. Cantor Fitzgerald reiterated an “underweight” rating and issued a $69.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday. Finally, Wells Fargo & Company reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $205.48.

Intercept Pharmaceuticals (ICPT) traded down 3.52% during midday trading on Thursday, hitting $87.56. 2,046,829 shares of the stock traded hands. The stock’s market capitalization is $2.20 billion. The stock’s 50-day moving average price is $111.73 and its 200-day moving average price is $116.97. Intercept Pharmaceuticals has a 52 week low of $85.88 and a 52 week high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The company had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same period last year, the business earned ($3.14) EPS. Equities research analysts expect that Intercept Pharmaceuticals will post ($14.06) EPS for the current fiscal year.

WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Stock Rating Reaffirmed by Cowen and Company” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/14/intercept-pharmaceuticals-inc-icpt-stock-rating-reaffirmed-by-cowen-and-company.html.

In other news, CFO Sandip Kapadia sold 1,431 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $121.59, for a total transaction of $173,995.29. Following the sale, the chief financial officer now owns 20,569 shares of the company’s stock, valued at approximately $2,500,984.71. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel G. Welch sold 217 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $126.76, for a total transaction of $27,506.92. Following the sale, the director now directly owns 3,710 shares in the company, valued at approximately $470,279.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,013 shares of company stock worth $6,198,747. Insiders own 9.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. WFG Advisors LP boosted its holdings in shares of Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Intercept Pharmaceuticals by 85.6% in the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 3,136 shares during the last quarter. Public Employees Retirement System of Ohio boosted its holdings in shares of Intercept Pharmaceuticals by 15.0% in the second quarter. Public Employees Retirement System of Ohio now owns 7,385 shares of the biopharmaceutical company’s stock worth $894,000 after buying an additional 965 shares during the last quarter. Asymmetry Capital Management L.P. purchased a new position in shares of Intercept Pharmaceuticals in the second quarter worth approximately $3,580,000. Finally, Nomura Holdings Inc. purchased a new position in shares of Intercept Pharmaceuticals in the second quarter worth approximately $366,000. 82.19% of the stock is currently owned by hedge funds and other institutional investors.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.